ArticleNature2019
WRN helicase is a synthetic lethal target in microsatellite unstable cancers.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 262 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
262citing papers in PubMed, 1 pooled it
19.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
262 citing papers in PubMed, 1 synthesis or guideline pooled it, 456 citations in OpenAlex.
- Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.Cell death & disease · 2022Pooled it
- CRISPR Screening Identifies SMARCAL1 and MRN as Modulators of WRN Dependency in MSI-H Colorectal Cancer.Cancer research · 2026Article
- Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release.Cancer research · 2026Article
- Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.Nature medicine · 2026Article
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- Replication stress in cancer: origins, consequences and therapeutic opportunities.Nature reviews. Cancer · 2026Review
- DNA binding contributes to dominant-negative effects of a catalytically inactive RecQ4-family helicase.Nucleic acids research · 2026Article
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Suppression of transcription-replication conflicts by sequence-coordinated actions of TRDMT1 and MutLα.Nature communications · 2026Article
- Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors.Molecular cancer therapeutics · 2026Article
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Organoid technology in cancer research.Molecular biomedicine · 2026Review
- Differential DNA damage response to WRN inhibition identifies a targetable vulnerability inScience advances · 2026Article
- Using cancer profiles to identify synthetic lethal therapeutic targets and predictive biomarkers in cancer gene dependency data.Bioinformatics (Oxford, England) · 2026Article
- Synthetic lethality in cancer: mechanism exploration and therapeutic applications.Cell communication and signaling : CCS · 2026Review
- Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states.Nature protocols · 2026Review
- Pancancer Fine-Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Increased vulnerability of colorectal cancer models with high alkylation damage to NTHL1 inactivation.Scientific reports · 2026Article
- GEMap: A comprehensive gene essentiality map for drug discovery.Acta pharmaceutica Sinica. B · 2026Article
- Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer.Clinical and molecular hepatology · 2026Article
202 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
41 authors at 7 institutions in 1 country.
Edmond M Chan *Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Tsukasa Shibue *Broad Institute of Harvard and MIT, Cambridge, MA, USA.
James M McFarlandBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Benjamin GaetaBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Mahmoud GhandiBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Nancy DumontBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Alfredo GonzalezBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Justine S McPartlanBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Tianxia LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Yanxi ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jie Bin LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jean-Bernard LazaroDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Peili GuDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
Cortt G PiettDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Annie ApffelBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Syed O AliBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Rebecca DeasyBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Paula KeskulaBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Raymond W S NgBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Emma A RobertsDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Elizaveta ReznichenkoDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Lisa LeungBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Maria AlimovaBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Monica SchenoneBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Mirazul IslamBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Yosef E MaruvkaBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Yang LiuBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Jatin RoperDepartment of Medicine, Division of Gastroenterology, Duke University, Durham, NC, USA.
Srivatsan RaghavanBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Marios GiannakisBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Yuen-Yi TsengBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Zachary D NagelBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Alan D'AndreaDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
David E RootBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Jesse S BoehmBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Gad GetzBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Sandy ChangDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
Todd R GolubBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Aviad TsherniakBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Francisca Vazquez *Broad Institute of Harvard and MIT, Cambridge, MA, USA. vazquez@broadinstitute.org.
Adam J Bass *Broad Institute of Harvard and MIT, Cambridge, MA, USA. adam_bass@dfci.harvard.edu.
Broad Institute · USDana-Farber Cancer Institute · USHarvard University · USYale University · USDuke University · USHoward Hughes Medical Institute · USMassachusetts General Hospital · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MSTRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MThe role of Mtss1 in Hedgehog-mediated intestinal cancer stem cell functionK08CA198002 · NCI · TUFTS MEDICAL CENTER · PI ROPER, JATIN · 2015 to 2019
$845kNCI NIH HHS K08 CA198002NCI NIH HHS P30 CA014236NCI NIH HHS T32 CA009172NIDDK NIH HHS P30 DK034854
Abstract
Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer therapeutics
Indexed as
Microsatellite InstabilityApoptosisCell Cycle CheckpointsCell Line, TumorCRISPR-Cas SystemsDNA Breaks, Double-StrandedHumansMicrosatellite RepeatsModels, GeneticNeoplasmsRNA InterferenceSynthetic Lethal MutationsTumor Suppressor Protein p53Werner Syndrome HelicaseTP53 protein, humanTumor Suppressor Protein p53Werner Syndrome HelicaseWRN protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.